Dr. Toby Eyre, a consultant haematologist at the University of Oxford in the UK, joins the hosts to review the hottest updates in lymphoma from the ASH 2023 meeting. They discuss topics like the promising results of a novel triplet treatment for mantle cell lymphoma and the challenges of conducting trials in high-risk groups. They also explore the question of stopping therapy without consolidation, the use of a BCL2 inhibitor in lymphoma treatment, and the comparison of different treatments for CLL and Hodgkin lymphoma.

Experts Toby Eyre and Lydia Scarfò discuss the latest updates in CLL treatment, including BTK and BCL2 inhibitor combinations, BTK degraders, and the role of epcoritamab in Richter’s transformation. They explore the trade-off between toxicity and efficacy, potential sequencing strategies, and promising results in heavily pretreated CLL patients, offering insights on future treatments and clinical trials.